Hexachlorobenzene
CASRN 118-74-1
- IRIS Summary (PDF) (16 pp, 129 K)
Noncancer Assessment
Reference Dose for Oral Exposure (RfD) (PDF) (16 pp, 129 K)
Last Updated: 09/26/1988
| System | RfD (mg/kg-day) | Basis | PoD | Composite UF | Confidence |
|---|---|---|---|---|---|
| Hepatic | 8 x 10-4 | Liver effects |
NOAEL
: 8 x 10-2 mg/kg-day |
100 | Medium |
Reference Concentration for Inhalation Exposure (RfC) (PDF) (16 pp, 129 K)
Last Updated: 03/01/1991
Information reviewed but value not estimated.
Cancer Assessment
Weight of Evidence for Cancer (PDF) (16 pp, 129 K)
Last Updated: 03/01/1991
| WOE Characterization | Framework for WOE Characterization |
|---|---|
| B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) |
- Hexachlorobenzene, when administered orally, has been shown to induce tumors in the liver, thyroid and kidney in three rodent species.
- This may be a synopsis of the full weight-of-evidence narrative.
Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (16 pp, 129 K)
Oral Slope Factor:
1.6 per mg/kg-day
Drinking Water Unit Risk:
4.6 x 10 -5 per µg/L
Extrapolation Method:
Linearized multistage, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (Erturk et al., 1986)
Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (16 pp, 129 K)
Inhalation Unit Risk:
4.6 x 10 -4 per µg/m3
Extrapolation Method:
Linearized multistage, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (Erturk et al., 1986)
You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.
